Venus gets market authorisation from Swiss drug authority

Tags: Companies
Pharma major Venus Remedies has secured its first marketing authorisation in Switzerland from Swiss drug authority 'Swissmedic' for its oncology drug 'Gemcitabine'.

The marketing approval for Gemcitabine will help the company further strengthen its oncology portfolio and improve its presence in this space, Venus Remedies said in a statement here today.

The Panchkula-based company plans to launch the drug early next quarter and the product will be launched in Switzerland by Swiss Pharma GmbH, with which Venus has a marketing tie-up, it said.

"The launch of this product will add to the company's top line and bottom line in the coming quarters," it said.

Venus Remedies has already received more than 20 marketing approvals for Gemcitabine injection from various countries. The product is being sold in the UK, Poland and Germany.

Gemcitabine is an anti-cancer drug used for the treatment of a variety of cancerous conditions, including the cancer of the lungs, pancreas, bladder and breast.

EDITORIAL OF THE DAY

  • Trade policies must not ring fence specific industry sectors

    Within days of the government setting a floor price for import of steel products to thwart countries such as China from undercutting local mills, gove

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Arun Kumar Jain

Reframe mindset to achieve excellence

Niels Bohr, the famous quantum physicist on­ce said, “The opposite ...

Kuruvilla Pandikattu

More real than the reality

Virtual reality (VR), a te­chnology that offers an un­imaginably altered ...

Dharmendra Khandal

Urbanisation is costing us our wildlife

The road transport and highways minister Nitin Gadkari aims to ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture